Clinical 2011 - 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy

Abstracts should contain the following 4 components (please bold the four section headings noted below within the text of your abstract submission).

Background: a concise statement of the issue under investigation or a hypothesis;
Methods: the experimental methods used (including the statistical analyses employed);
Results: specific findings (promises such as "to be completed" or "to be presented" are not acceptable); and
Conclusions: a summary of findings that are supported by your results (statistical analyses used to support the conclusions, where appropriate, should be included; concluding statements such as "the results will be discussed" are not acceptable).

Please note that abstracts cannot be accepted if tables, graphs, grant acknowledgements or literature references are included.
The maximum word count for the abstract body is 500 words.

Abstracts are considered official communications to the conference and will be treated confidentially. For those abstracts that are accepted, submitters agree to attend the meeting and present their abstract as scheduled.

Policy regarding the inclusion of chemical structures
Since this workshop is dedicated to discussion of new HCV antivirals and the development of drug resistance, the inclusion of the chemical structures of new compounds in presentations is considered germane to the scientific discussion, and is strongly encouraged. Under some circumstances where the specific structure of a lead compound cannot be disclosed, substitution of a more generic structure which provides information on a compound series may be appropriate.

Abstract submission
Authors can submit their abstracts electronically per 1 March 2011 using the button on the right hand side. This will direct you to the appropriate webpage.
Please follow the step-by-step directions to upload the abstract file from your computer to our system. To ensure your abstract retains any special characters or formatting, the abstract must be in Microsoft Word format.

Categories for abstract submission
For purposes of review and programming, abstracts are divided into topical categories. Selection of the most appropriate category is important as it determines who reviews your abstract. The Program Committee reserves the right to reassign your abstract to a more appropriate category.

Topics:

- Advanced Investigations in Pharmacology

- Drug Interactions

- Novel drug formulations

- Pharmacogenetics

- PK/PD modeling

- PK/PD of Drug Efficacy and Toxicity

- Clinical Pharmacology in Special patient groups

Notification of abstract acceptance/rejection and presentation format
Notifications of acceptance and format of presentation (oral or poster presentation) will be e-mailed (or faxed if you did not supply an e-mail address) to submitting authors in the third week of May. It is the responsibility of the corresponding/presenting author to inform all co-authors of the abstract’s status. Please notify the Conference Secretariat if you have not received notification by the end of May.

If an abstract is accepted, one author is required to register for the conference and present the paper as scheduled. A special registration form that will be sent together with the notification may be used by the attending author to apply for the regular registration fee. Guidelines for preparing your oral and/or poster presentations will be sent after your abstract has been accepted.

Abstract publication
Accepted abstracts will be published in the final Program/abstract Book, which will be distributed during the conference. In addition, all abstracts will be published in the journal Reviews in Antiviral Therapy. Please note that the conference secretariat cannot be held responsible for any typing or language errors in the submitted abstracts as only the format of the abstracts will be changed and not the content.